US Edition
Published • loading... • Updated
EU Approves Higher Dose of Novo Nordisk's Wegovy
Clinical trials showed adults on the 7.2 mg Wegovy dose lost about 21% of body weight, offering a new option when lower doses are insufficient, the European Commission said.
- On 17 February 2026, the European Commission granted final approval of a higher 7.2 mg maintenance dose of Wegovy for adults living with obesity, announced from Bagsværd, Denmark.
- Regulators cited evidence from STEP UP and STEP UP T2D late-stage trials showing larger weight loss with the 7.2 mg dose, including a 72-week trial with 1,407 adults where 7.2 mg lost 20.7% versus 17.5% for 2.4 mg.
- Doctors in the EU may prescribe Wegovy 7.2 mg as a single-dose pen, with tests showing preserved muscle function and body composition data, and patients can step from Wegovy 2.4 mg after four weeks.
- Already approved in the UK, Wegovy's 7.2 mg rollout allows EU healthcare professionals to prescribe the dose as three injections, with applications pending with the US FDA.
- The evidence base extends to people with type 2 diabetes, as STEP UP T2D broadens applicability; label data include MACE risk reduction, HFpEF symptoms, knee osteoarthritis pain, and Novo Nordisk's global scale may influence uptake.
Insights by Ground AI
12 Articles
12 Articles
The European Commission has granted final approval for a higher dose of the weight loss drug Wegovy in injectable form. Novo Nordisk writes in a press release. The approval applies to a weekly...
·Aarhus, Denmark
Read Full Article
Novo Nordisk A/S: The European Commission approves more effective dose of injectable Wegovy® for adults with obesity; clinical study showed people lost about 21% of their body weight on average
Final EU approval of high-maintenance dose of Wegovy. The new dose gives healthcare professionals even more flexibility to tailor treatment....
Coverage Details
Total News Sources12
Leaning Left0Leaning Right2Center5Last UpdatedBias Distribution71% Center
Bias Distribution
- 71% of the sources are Center
71% Center
C 71%
R 29%
Factuality
To view factuality data please Upgrade to Premium
